Valuation: CellSource Co., Ltd.

Market Cap 6.43B 39.24M 34.51M 32.06M 29.49M 55.3M 3.8B 56.29M 383M 150M 1.85B 147M 144M P/E 2026 *
108x
P/E 2027 * 58.9x
Enterprise Value 6.43B 39.24M 34.51M 32.06M 29.49M 55.3M 3.8B 56.29M 383M 150M 1.85B 147M 144M EV / Sales 2026 *
1.79x
EV / Sales 2027 * 1.69x
Free-Float
45.73%
Yield 2026 *
-
Yield 2027 * -
1 day-1.23%
1 week-6.43%
Current month+2.56%
1 month+6.67%
3 months-13.04%
6 months-20.20%
Current year-19.80%
1 week 320
Extreme 320
342
1 month 296
Extreme 296
358
Current year 294
Extreme 294
442
1 year 294
Extreme 294
723
3 years 294
Extreme 294
2,600
5 years 294
Extreme 294
8,160
10 years 294
Extreme 294
8,160
Manager TitleAgeSince
Chief Executive Officer 62 2025-10-31
Director of Finance/CFO - 2025-12-31
Corporate Officer/Principal - 2023-12-31
Director TitleAgeSince
Director/Board Member 64 2017-05-31
Chairman 62 2024-01-24
Director/Board Member 57 2022-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.23%-6.43%-55.12%-86.27% 40.03M
+0.11%-3.98%+13.89%-11.26% 66.25B
-0.12%+2.23%+36.63%+196.27% 52.86B
+0.51%+37.90%+37.90%+37.90% 43.01B
-1.05%-7.04%-57.47%-56.95% 39.52B
+1.46%-3.97%+53.17%-27.51% 29.19B
+0.78%+0.03%+65.07%+81.90% 23.13B
-1.81%-9.71%+64.46%-54.90% 23.04B
-0.55%+1.69%+2.55%+172.44% 20.48B
-1.04%-1.59%+66.57%+119.96% 16.6B
Average -0.30%-2.72%+22.77%+37.16% 31.41B
Weighted average by Cap. -0.09%-2.30%+25.19%+45.70%

Financials

2026 *2027 *
Net sales 3.6B 21.97M 19.32M 17.95M 16.51M 30.96M 2.13B 31.51M 215M 83.72M 1.04B 82.47M 80.69M 3.8B 23.19M 20.39M 18.95M 17.43M 32.68M 2.25B 33.26M 227M 88.37M 1.1B 87.05M 85.17M
Net income 60M 366K 322K 299K 275K 516K 35.46M 525K 3.58M 1.4M 17.29M 1.37M 1.34M 110M 671K 590K 548K 504K 946K 65.01M 963K 6.56M 2.56M 31.71M 2.52M 2.47M
Net Debt - -
Logo CellSource Co., Ltd.
CellSource Co., Ltd. is a Japan-based company engaged in regenerative medicine related business and consumer business. The Company operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.
Employees
148
Date Price Change Volume
26-07-23 JP¥320.00 -1.23% 5,400
26-07-23 JP¥324.00 -1.52% 21,600
26-07-22 JP¥329.00 -1.20% 25,400
26-07-21 JP¥333.00 -2.63% 25,900
26-07-17 JP¥342.00 -0.29% 42,200
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4880 Stock